
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Here are some highlights from Frank A. Clark, MD’s, Poetry for Inclusion from throughout 2023, as seen in Psychiatric Times.




